Harvey Pass
NYU Langone Medical Centre, NY, United States
- This delegate is presenting an abstract at this event.
Dr. Pass is the Stephen E. Banner Professor of Thoracic Oncology, Director of General Thoracic Surgery, and Vice Chair for Research for the Department of Cardiothoracic Surgery for the
NYU Langone Medical Center.
Dr. Pass is a surgeon scientist whose work focuses on the early detection, surgical management, and adjuvant therapy of thoracic malignancies. From 1986-1996, Dr. Pass was Senior Investigator and Chief of the Division of Thoracic Oncology in the Surgery Branch of the National Cancer Institute, Bethesda, Maryland. He joined NYU Langone Medical Center in October 2005 from Wayne State University in Detroit where he was Professor of Surgery and Chief of Thoracic Oncology for 9 years. Dr. Pass is recognized for his work in lung cancer and mesothelioma, and has been continuously funded by the DOD, NCI, and the CDC among others since 1998 for discovery and/or validation of blood-based biomarkers including osteopontin and fibulin. He has designed and published 9 physician-initiated trials of novel therapies for lung cancer and mesothelioma among his 400 peer-reviewed publications. Dr. Pass has published 10 books including 4 editions of Lung Cancer: Principles and Practice, Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis and Translational Therapies, and two editions of 100 Questions and Answers about Mesothelioma. He is the Editor of Seminars in Thoracic And Cardiovascular Surgery, and he is on the Editorial Board of Clinical Lung Cancer, Clinical Cancer Research, Current Treatment Options in Oncology, and Cancer Biomarkers. He has been on the Board of Directors for the International Association for the Study of Lung Cancer, the International Mesothelioma Interest Group, the Lung Cancer Alliance, and the Mesothelioma Applied Research Foundation. Dr. Pass has been the recipient of the NIH Directors Award, the Wagner Medallion for contributions to the study of mesothelioma, the Pioneer Award from the Mesothelioma Foundation, and the Landon Award for Team Science from the American Association for Cancer Research.
Presentations this author is a contributor to:
Targeting the RON/MST1R receptor using LCRF004, may provide an effective novel interventional strategy in malignant pleural mesothelioma (#206)
3:15 PM
Anne-Marie Baird
Best of the Best Poster discussion B - Researching cancer treatments
Biomarker studies in lung cancer and mesothelioma (#82)
12:00 PM
Harvey Pass
Concurrent session - Emerging technologies
Surgery for Lung Cancer 2014: CT Nodule Stratification and Management (#71)
9:30 AM
Harvey Pass
Plenary - Recent improvements in lung cancer care; what you must know